About Us
We are a clinical-stage biopharmaceutical company leveraging our proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases.
Our platform enables us to strategically pair linker-payloads that modulate key disease-modifying pathways with monoclonal antibodies directed to specific disease sites.
Initially, we are creating a new class of targeted immuno-oncology agents that direct a myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing.
Our Purpose
Inspired by patients. Driven by data. Powered by science. These are just a few values that help describe who Silverback is, but our commitment and purpose go deeper.
Our Purpose
Inspired by patients. Driven by data. Powered by science. These are just a few values that help describe who Silverback is, but our commitment and purpose go deeper.